Royalty Pharma Plc Stock Price, News & Analysis

Royalty Pharma (NASDAQ:RPRX) presented its Investor Day outlook, highlighting strong growth projections and value creation plans. The company aims to deliver Portfolio Receipts of $4.7 billion or more by 2030, exceeding consensus expectations. Since its 2020 IPO, RPRX has achieved a 12% compound annual growth rate in Portfolio Receipts and demonstrated robust financial performance with a 15% Return on Invested Capital (ROIC) and 21% Return on Invested Equity (ROIE).

The company has already deployed $9 billion of its $10-12 billion five-year capital deployment target, with $14 billion in announced transactions. The biopharma royalty market has doubled since RPRX's IPO, averaging $6.2 billion in annual transaction value. The company targets at least mid-teens average annual total shareholder return through 2030, supported by double-digit growth and dividend increases.

Royalty Pharma (NASDAQ:RPRX) announced the release of a groundbreaking Deloitte report on the biopharma royalty market. The study, titled "Role of Royalties in Funding Biopharma Innovation," gathered insights from over 110 biopharma executives, primarily CEOs and CFOs.

The report reveals that 87% of surveyed executives would consider royalties for capital raising in the next three years. Key benefits highlighted include non-dilutive nature, absence of covenants, operational control retention, single-product financing capability, and available capital scale. The study emphasizes royalties' growing importance in biopharma's diversified funding landscape, driven by positive investor perception and attractive cost of capital.

Royalty Pharma (NASDAQ:RPRX) has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will engage in a fireside chat on Tuesday, September 9, 2025, at 3:20 p.m. ET. Investors can access the webcast through Royalty Pharma's "Events" page on their investor relations website, where it will remain archived for at least thirty days.

Royalty Pharma (Nasdaq: RPRX) has announced the pricing of $2.0 billion in senior unsecured notes across three tranches: $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950% Notes due 2055.

The notes will be guaranteed by Royalty Pharma Holdings Ltd and Royalty Pharma Manager, LLC. The offering is expected to close on September 16, 2025. The company plans to use the proceeds for general corporate purposes. Multiple financial institutions, led by BofA Securities, Goldman Sachs, J.P. Morgan, Morgan Stanley, and TD Securities, are serving as joint book-running managers.

Royalty Pharma (Nasdaq: RPRX) has entered into a significant funding agreement with Zenas BioPharma for up to $300 million in exchange for royalties on obexelimab sales. The deal includes an upfront payment of $75 million and three additional $75 million payments tied to clinical and regulatory milestones.

The funding will support obexelimab's development and potential commercial launch for IgG4-Related Disease (IgG4-RD) in early 2027. Royalty Pharma will receive a 5.5% royalty on worldwide net sales. The drug is currently in Phase 3 trials for IgG4-RD and Phase 2 trials for Multiple Sclerosis and Systemic Lupus Erythematosus, with key trial results expected around year-end.

Royalty Pharma (NASDAQ:RPRX) has announced the acquisition of a royalty interest in Amgen's Imdelltra from BeOne Medicines for $885 million upfront, with an additional $65 million option available to BeOne within 12 months. The deal involves approximately 7% royalty on worldwide net sales of Imdelltra, extending through 2038-2041.

Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), received FDA accelerated approval in May 2024 for treating extensive-stage small cell lung cancer. The drug achieved $215 million in sales during H1 2025 and is projected to reach $2.8 billion by 2035. The agreement includes royalty sharing with BeOne on annual net sales above $1.5 billion, while BeOne retains China commercial rights.

BeOne Medicines (Nasdaq: ONC) has entered into a significant royalty purchase agreement with Royalty Pharma for up to $950 million for IMDELLTRA® worldwide sales rights (excluding China). The deal includes an $885 million upfront payment and a potential additional $65 million within 12 months.

IMDELLTRA® is a groundbreaking DLL-3 targeting bispecific T-cell engager approved for treating extensive-stage small cell lung cancer (ES-SCLC) patients who have progressed after platinum-based chemotherapy. BeOne will retain a portion of royalties on annual sales above $1.5 billion and maintain rights to other assets under its Amgen collaboration, including xaluritamig.

Royalty Pharma (NASDAQ:RPRX) announced that Henry Fernandez has stepped down from his position as Lead Independent Director on the company's Board of Directors, effective August 13, 2025. Fernandez joined the board in July 2020 and was appointed Lead Independent Director in March 2021.

During his tenure, Fernandez contributed to several company milestones, including the completion of internalization. CEO Pablo Legorreta praised Fernandez's leadership and business expertise, particularly valuable during Royalty Pharma's early years as a public company. The company plans to appoint a new Lead Independent Director in the near future.

Royalty Pharma (NASDAQ:RPRX) reported strong Q2 2025 results with Portfolio Receipts growing 20% to $727 million and Royalty Receipts increasing 11% to $672 million. The company raised its full-year 2025 guidance, now expecting Portfolio Receipts between $3,050-$3,150 million, representing 9-12% growth.

Key Q2 highlights include the completion of external manager acquisition, a groundbreaking $2 billion funding agreement with Revolution Medicines, and $1 billion in share repurchases during H1 2025. The company maintained strong liquidity with $632 million in cash and $8.2 billion in total debt as of June 30, 2025.

Growth was primarily driven by strong performance from products including Voranigo, Trelegy, Evrysdi, and Tremfya, while positive clinical updates were reported across the portfolio, notably for Gilead's Trodelvy in breast cancer treatment.